TEVA Q2 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.2B+0.3% YoY

Gross Profit

$2.1B50.3% margin

Operating Income

$455M10.9% margin

Net Income

$282M6.8% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

$227M

Free Cash Flow

$131M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$40.1B

Total Liabilities

$33.3B

Stockholders' Equity

$6.8B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.2B	$4.2B	+0.3%
Gross Profit	$2.1B	$2.0B	+3.9%
Operating Income	$455M	-$5M	+9200.0%
Net Income	$282M	-$846M	+133.3%

Revenue Segments

Product

$3.6B87%

Distribution Service

$377M9%

Product and Service, Other

$117M3%

License

$46M1%

Geographic Segments

United States Segment

$2.2B55%

Europe Segment

$1.3B33%

International Markets

$495M13%